|
Positive HBsAg at baseline (N = 74)
|
|
Participants achieving 0.25 log10 HBsAg reduction from baseline
|
|
HBsAg ≤ −0.25 log10, n (%), [95% CI]
|
–
|
3 (4), [0.8, 11.4]
|
9 (12), [5.7, 21.8]
|
|
Participants achieving HBsAg seroclearance
| |
0
|
0
|
|
Participants achieving HBsAg/anti-HBs seroconversiona
| |
0
|
0
|
|
Change from baseline in HBsAg (log10 IU/mL)
| | | |
|
Mean (SD), [95% CI]
|
3.52 (0.46), [3.41, 3.62]b
|
−0.11 (0.08), [−0.13, −0.10]c
|
−0.14 (0.12), [−0.17, −0.11]a
|
|
Positive HBeAg at baseline (N = 69)
|
|
Participants achieving HBeAg seroclearance, n (%)
| |
8 (12)
|
17 (25)
|
|
Participants achieving HBeAg/anti-HBe seroconversion,d n (%)
| |
7 (13)
|
13 (25)
|
|
Change from baseline in HBcrAg (N = 74), (log10 U/mL)
|
|
Mean (SD), [95% CI]
|
5.53 (0.54), [5.40, 5.65]b
|
−0.17 (0.29), [−0.23, −0.10]c
|
−0.30 (0.36), [−0.38, −0.22]a
|
|
Change from baseline in HBV-DNA (N = 74), (log10 IU/mL)
|
|
Mean (SD), [95% CI]
|
0.92 (0.12), [0.89, 0.95]b
|
−0.02 (0.10), [−0.04, 0.01]c
|
−0.02 (± 0.12), [−0.05, 0.01]a
|
